Chronic intrathecal baclofen administration for control of severe spasticity.

@article{Lazorthes1990ChronicIB,
  title={Chronic intrathecal baclofen administration for control of severe spasticity.},
  author={Yves Lazorthes and B. Sallerin-Caute and J. C. Verdi{\'e} and R. Bastide and J. P. Carillo},
  journal={Journal of neurosurgery},
  year={1990},
  volume={72 3},
  pages={
          393-402
        }
}
Baclofen, the most effective drug for treating spasticity, is a specific agonist of gamma-aminobutyric acid-B receptors, and is very abundant in the superficial layers of the spinal cord. Given orally, baclofen does not easily penetrate the blood-brain barrier, and is distributed equally to the brain and spinal cord. Direct intrathecal administration was given in order to change the distribution of the drug by preferentially perfusing the spinal cord. Eighteen patients presenting a severe… 
View on PubMed
thejns.org
188 Citations
Highly Influential Citations
6
Background Citations
36
Methods Citations
2
Results Citations
3

188 Citations

Citation Type

Citation Type

Intrathecal Baclofen for Dystonia and Related Motor Disorders
TLDR
Clinical investigators considered that Intrathecal baclofen (ITB) might benefit dystonia patients, especially for individuals unable to tolerate high oral doses of bacl ofen.
Intrathecal baclofen for treatment of intractable spinal spasticity.
Topical Review: Baclofen in the Treatment of Cerebral Palsy
TLDR
Preliminary studies indicate that continuous intrathecal baclofen infusion alleviates some forms of generalized dystonia associated with cerebral palsy and improves upper extremity function and activities of daily living.
Use of intrathecal baclofen in the treatment of patients with dystonia.
TLDR
It is concluded that the role of IT baclofen in treating severe dystonia remains uncertain and intrathecal bacl ofen may be more effective when dySTONia is associated with spasticity or pain.
Intrathecal baclofen in the treatment of spasticity.
TLDR
Intrathecal baclofen is currently the most effective means of treating diffuse abnormal spasticity of both cerebral and spinal origin in the adult and pediatric patient.
Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries
TLDR
It is demonstrated that chronic intrathecal baclofen infusion is a safe and effective form of treatment of intractable spasticity in patients with spinal cord injury and considerable reduction in the risk of infection in view of the fact that interrogation and programming of the implanted programmed pumps is noninvasive.
Intrathecal baclofen for treating spasticity in children with cerebral palsy.
TLDR
There is some limited short-term evidence that intrathecal baclofen is an effective therapy for reducing spasticity in children with cerebral palsy.
Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin.
TLDR
The results demonstrate the potential value of continuous intrathecal baclofen infusion for treatment of severe spasticity of cerebral origin, however, this treatment can result in significant complications and more experience is required before the long-term benefits can be determined.
Intrathecal Baclofen for Severe Spasticity Secondary to Spinal Cord Injury
TLDR
Intrathecal administration achieves high concentrations in the spinal cord with small dosages, thus reducing the incidence of central nervous system adverse effects and the question of whether tolerance detracts from long-term clinical benefits with intrathecal baclofen needs to be addressed.
Intrathecal baclofen infusion: an innovative approach for controlling spinal spasticity.
  • S. Savoy, J. Gianino
  • Medicine
    Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses
  • 1993
TLDR
An innovative therapy for controlling spasticity is introduced and the nurse's role in patient selection and management is discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Intrathecal application of baclofen in the treatment of spasticity.
TLDR
Baclofen, in comparison with some other drugs such as morphine or midazolam, also tried intrathecally by the authors, is the most effective in reducing spasticity; its use however warrants caution, for it can cause decreased consciousness, and there is currently no antagonist.
Chronic Intrathecal Administration of Baclofen in Treatment of Severe Spasticity
TLDR
Although baclofen is the most frequently used antispastic drug in the treatment of spasticity, particularly of spinal origin, effective treatment requires high dosage usually in the range of 40–80 mg per day orally, side effects correlate with the dosage necessary to obtain a therapeutic effect.
Long-term intrathecal baclofen infusion for treatment of spasticity.
TLDR
Seven patients with spasticity of spinal cord origin have been maintained for up to 2 years with continuous spinal intrathecal infusion of baclofen, with the greatest benefits to the patients improvement in activities of daily living and better sleep due to reduced spasms.
Chronic Intrathecal Baclofen for Severe Rigidity and Spasms
TLDR
The lack of effect of baclofen in many patients and the only mild reduction in symptoms raises the question of whether efficacy is limited by the route of administration or if the drug intrinsically is limited in its effects.
CONTINUOUS INTRATHECAL BACLOFEN FOR SEVERE SPASTICITY
Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis.
Intrathecal baclofen for treatment of spasticity.
TLDR
The paper by Ochs et al' confirms the findings of Dr Penn et al 23 that chronic intrathecal administration of baclofen may be effective in relieving spasticity due to spinal cord damage and confirms that the response of intratheCal bacl ofen will vary according to the underlying pathological process.
The effect of intrathecal baclofen on electrical muscle activity in spasticity
TLDR
The efficacy of intrathecally administered baclofen was demonstrated in three patients with different types of muscular hypertonia using integrated electromyography and may be considered as a possible alternative to surgery.
Are baclofen-sensitive GABAB receptors present on primary afferent terminals of the spinal cord?
TLDR
It is reported here that GABAB sites, unlike GABAA sites, are present in high concentrations in laminae I, II, III and IV of the dorsal horn and that after the neonatal administration of capsaicin this binding is reduced by 40–50%.
δ-Aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system
TLDR
Evidence is presented that AVA antagonizes central pharmacological actions of baclofen at both spinal and supraspinal sites without affecting the actions of a GABAA agonist, muscimol.
...
1
2
3
4
5
...